Business Context and Reporting Period
Company: Instil Bio, Inc. (Nasdaq: TIL)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2025
Business Overview: Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. In January 2026, the company announced the discontinuation of its former lead product candidate, AXN-2510, and the termination of its collaboration with ImmuneOnco. The company currently has no product candidates in active development and is seeking to in-license or acquire new assets. It operates as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(71,372) | $(74,135) |
| Total Operating Expenses | $78,581 | $73,541 |
| Research & Development Expenses | $24,738 | $11,838 |
| General & Administrative Expenses | $27,221 | $44,210 |
| Restructuring & Impairment Charges | $16,622 | $7,493 |
| Cash, Cash Equivalents, and Marketable Securities | $76,300 | $114,145 |
| Accumulated Deficit | $(726,488) | $(655,116) |
| Debt (2024 Loan Principal) | $85,600 | $85,600 |
Note: The company generated no product revenue. Other rental income from the Tarzana facility was $8.97 million in 2025.
Material Changes vs. Prior Period
- Discontinuation of Lead Asset: In January 2026, the company discontinued development of AXN-2510 and terminated the collaboration agreement with ImmuneOnco. This follows a strategic shift after previously discontinuing its CoStAR-TIL cell therapy program.
- Increased R&D Spend: Research and development expenses increased by $12.9 million (109%) to $24.7 million, primarily driven by costs related to the AXN-2510 clinical trial and collaboration activities prior to termination.
- Decreased G&A Spend: General and administrative expenses decreased by $17.0 million (38%) to $27.2 million, largely due to reduced headcount and lower stock-based compensation.
- Significant Impairment: Restructuring and impairment charges increased by $9.1 million to $16.6 million. This was primarily due to a $16.6 million impairment loss on the Tarzana, California facility, which was classified as held for sale.
- Debt Refinancing: In December 2024, the company refinanced its construction loans with a new $85.6 million term loan (the "2024 Loan") maturing in January 2027.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has identified an indicator of substantial doubt about the company's ability to continue as a going concern. The $85.6 million term loan matures in January 2027, exceeding the company's current cash and marketable securities ($76.3 million). Management plans to exercise a contractual one-year extension option to January 2028, sell the Tarzana facility, or seek additional financing to alleviate this doubt.
- Liquidity Outlook: As of December 31, 2025, the company held $76.3 million in cash, cash equivalents, and marketable securities. Management believes these resources, combined with the loan extension option, are sufficient to fund operations beyond 2027.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to pursue its strategy of in-licensing or acquiring new product candidates.
- Key Risks:
- No Active Pipeline: The company currently has no product candidates in active development and no history of completing clinical trials or commercializing products.
- Debt Covenants: Failure to meet financial covenants or refinance the 2024 Loan could result in an event of default, potentially leading to the lender taking control of the Tarzana facility.
- Asset Sale Uncertainty: Proceeds from the sale of the Tarzana facility may be insufficient to repay the secured debt encumbering it.
Investor Verification Checklist
- Debt Maturity & Extension: Verify the specific conditions required to exercise the one-year extension option on the $85.6 million term loan maturing in January 2027.
- Tarzana Facility Valuation: Confirm the current fair value of the Tarzana facility (classified as held for sale at $112.1 million) and the likelihood of a sale price sufficient to cover the $85.6 million debt obligation.
- Pipeline Strategy: Assess the company's progress in identifying, in-licensing, or acquiring new therapeutic candidates to replace the discontinued AXN-2510 program.
- Cash Burn Rate: Monitor the rate of cash consumption relative to the $76.3 million liquidity position to ensure sufficiency until the next financing event or asset sale.
- Going Concern Status: Review future filings for updates on the "substantial doubt" regarding the company's ability to continue as a going concern.